July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Results of Aflibercept in Hispanics with retinal vein occlusion macular edema
Author Affiliations & Notes
  • Francisco J Rodriguez
    Fundacion Oftalmologica Nacional, Bogota, Colombia
  • Shirley Margarita Rosenstiehl
    Fundacion Oftalmologica Nacional, Bogota, Colombia
  • Diana Alejandra Cortes
    Fundacion Oftalmologica Nacional, Bogota, Colombia
  • Claudia Rosa Carvajal
    Fundacion Oftalmologica Nacional, Bogota, Colombia
  • Footnotes
    Commercial Relationships   Francisco J Rodriguez, None; Shirley Rosenstiehl, None; Diana Cortes, None; Claudia Carvajal, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 397. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francisco J Rodriguez, Shirley Margarita Rosenstiehl, Diana Alejandra Cortes, Claudia Rosa Carvajal; Results of Aflibercept in Hispanics with retinal vein occlusion macular edema. Invest. Ophthalmol. Vis. Sci. 2018;59(9):397.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Introduction:
Retinal vein occlusion (RVO) can cause vision loss secondary to macular edema. Currently, the most common therapy used is intravitreal inhibition of vascular endothelial growth factor (VEGF).

Propose: To describe the functional and anatomic results of intravitreal aflibercept
for macular edema associated to retinal vein occlusion in a Hispanic population

Methods : Methods: Retrospective chart and ancillary tests review of patients with either central (CRVO) or branch (BRVO) retinal vein occlusion and associated macular edema (ME) treated with aflibercept at Fundacion Oftalmologica Nacional.

Results : Results: 17 eyes of seventeen patients with a mean age of 54 years (SD 15.4), 64.7% men were included. CRVO was present in 58.8% patients and BRVO in 41.2%. A mean of 5 injections (range 3-9) of aflibercept were performed. Average follow-up was 8 months (range 3-25 months). Aflibercept was used de novo in 94% of the treated eyes. The visual acuity improved at least 1 line in 72% of the eyes, 36% gained ≥ 3 lines. The optical coherence central macular thickness before injections was 521 μ (250-988 μ), and 249 μ at the last follow-up visit, with an average change of 272 μ (p = 0.015).

Conclusions : Conclusions: Visual acuity improved or remained stable in most of the treated eyes and there was anatomic improvement in all eyes treated with Aflibercept in short and long follow-up time.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.